Aggressive Spinal HemangiomasNCT06996873
Aggressive Spinal Hemangioma
An observational study of Aggressive Spinal Hemangiomas, run by Assiut University.
Trial summary
This research is a case series analysis to evaluate aggressive vertebral hemangiomas. It focuses on clinical presentation, diagnostic imaging accuracy (X-ray, MRI, MSCT, angiography), and treatment efficacy. The primary goal is to establish optimal management protocols. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Aggressive Spinal Hemangiomas
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 30 Jun 2025to 30 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with symptomatic, radiologically confirmed aggressive spinal hemangiomas treated at Assiut University Hospital. Excludes incidentally discovered cases.
Who may be able to join
- Patients diagnosed with aggressive spinal hemangiomas based on clinical symptoms and imaging findings.
- Cases confirmed through diagnostic modalities such as X-ray, MRI, MSCT, or angiography.
- Patients presenting with symptoms such as pain, neurological deficits, or spinal instability attributable to the hemangioma.
Who cannot join
- Patients with incidentally discovered spinal hemangiomas (asymptomatic cases found during evaluations for unrelated conditions).
- Cases lacking sufficient diagnostic evidence to confirm aggressive spinal hemangioma.
About this study
Official title: Management Of Aggressive Spinal Hemangioma
This research is a case series analysis to evaluate aggressive vertebral hemangiomas. It focuses on clinical presentation, diagnostic imaging accuracy (X-ray, MRI, MSCT, angiography), and treatment efficacy. The primary goal is to establish optimal management protocols.
Read the detailed description
Hybrid methodology integrating retrospective case reviews (from Assiut University Hospital's Orthopedic Surgery Department) with synthesis of existing literature.
Objectives:
Characterize clinical presentations and imaging findings. Compare diagnostic accuracy across modalities. Analyze treatment outcomes, including procedural success rates and complications.
Tools:
Imaging: X-ray for initial screening, MRI/MSCT for soft tissue and spinal cord involvement, angiography for vascular mapping.
- Conditions
- Aggressive Spinal Hemangiomas
- Keywords
- hemangiomas, management
- Medical subject headings
- Hemangioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with symptomatic, radiologically confirmed aggressive spinal hemangiomas treated at Assiut | Confirmed diagnosis of aggressive vertebral hemangioma via imaging (MRI/MSCT) and clinical symptoms (e.g., pain, neurological deficits). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neurological Symptom Resolution
using the Pain intensity (VAS scale)
Measured: 3 months
Secondary outcomes (1)
Functional Status Improvement
using ASIA Impairment Scale (primary)
Threshold: ≥1-grade improvement on ASIA scale sustained for ≥3 months
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start30 Jun 2025 (estimated)
- Primary completion30 Jul 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aggressive Spinal HemangiomasStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Momen Ahmed Mohamed Kamel, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06996873
- Sponsor's protocol ID
- Spinal Hemangioma mangement
- Status last verified
- May 2025
- First submitted
- 2 Apr 2025
- Last updated
- 30 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Management Of Aggressive Spinal Hemangioma
- ClinicalTrials.gov ID
- NCT06996873
- Acronym / sponsor ID
- Spinal Hemangioma mangement
- Conditions
- Aggressive Spinal Hemangiomas
- Keywords
- hemangiomas, management
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 30 Jun 2025 (estimated)
- Primary completion
- 30 Jul 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research is a case series analysis to evaluate aggressive vertebral hemangiomas. It focuses on clinical presentation, diagnostic imaging accuracy (X-ray, MRI, MSCT, angiography), and treatment efficacy. The primary goal is to establish optimal management protocols.
Detailed description
Hybrid methodology integrating retrospective case reviews (from Assiut University Hospital's Orthopedic Surgery Department) with synthesis of existing literature.
Objectives:
Characterize clinical presentations and imaging findings. Compare diagnostic accuracy across modalities. Analyze treatment outcomes, including procedural success rates and complications.
Tools:
Imaging: X-ray for initial screening, MRI/MSCT for soft tissue and spinal cord involvement, angiography for vascular mapping.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with symptomatic, radiologically confirmed aggressive spinal hemangiomas treated at Assiut | – | –Confirmed diagnosis of aggressive vertebral hemangioma via imaging (MRI/MSCT) and clinical symptoms (e.g., pain, neurological deficits). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with symptomatic, radiologically confirmed aggressive spinal hemangiomas treated at Assiut University Hospital. Excludes incidentally discovered cases.
Key inclusion criteria (3 listed)
- Patients diagnosed with aggressive spinal hemangiomas based on clinical symptoms and imaging findings.
- Cases confirmed through diagnostic modalities such as X-ray, MRI, MSCT, or angiography.
- Patients presenting with symptoms such as pain, neurological deficits, or spinal instability attributable to the hemangioma.
Key exclusion criteria (2 listed)
- Patients with incidentally discovered spinal hemangiomas (asymptomatic cases found during evaluations for unrelated conditions).
- Cases lacking sufficient diagnostic evidence to confirm aggressive spinal hemangioma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Neurological Symptom Resolution
Time frame: 3 months
using the Pain intensity (VAS scale)
1 secondary outcome
Functional Status Improvement
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Aggressive Spinal Hemangiomas, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 May 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neurological Symptom Resolution (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2025.